FINANCINGS

Agile Therapeutics Inc. arranged a term loan of up to $25 million with Hercules Technology Growth Capital Inc.

Amag Pharmaceuticals Inc. priced its public offering of common stock for gross proceeds of about $175 million.

Bellerophon Therapeutics Inc. closed its IPO raising $60 million through the sale of 5 million shares priced at $12 each.

Celldex Therapeutics Inc. priced a public offering for $174 million in gross proceeds.

Curis Inc. priced a public offering resulting in aggregate proceeds of $60 million.

Inotek Pharmaceuticals Corp. closed its IPO of 6.7 million shares priced at $6 apiece for aggregate proceeds of $40 million.

Lion Biotechnologies Inc. priced a public offering for gross proceeds of $64 million.

Lyric Pharmaceuticals Inc. raised $20.4 million in a series A round.

Neos Therapeutics Inc. completed an oversubscribed round of financing, raising a total of $20.6 million.

Prexton Therapeutics SA, an early stage central nervous system drug developer, raised $10 million.

Relypsa Inc. priced its public offering for gross proceeds of about $150 million.

Xencor Inc. priced a public offering with gross proceeds expected to total about $106.9 million.

DEALS

Amarin Corp. plc entered an agreement with Eddingpharm Co. Ltd., which will develop and commercialize Vascepa in Mainland China, Hong Kong, Macao Special Administrative Regions and Taiwan.

Biota Pharmaceuticals Inc. entered a definitive agreement to acquire Anaconda Pharma.

Cerecor Inc. acquired rights from Eli Lilly and Co. to develop and commercialize LY2456302, a phase II-ready, selective kappa opioid receptor antagonist.

Heptares Therapeutics Ltd. is to be acquired by Sosei Group Corp. for $400 million.

Ipsen SA gained an exclusive option to purchase Canbex Therapeutics Ltd.

Foundation Medicine Inc. and H3 Biomedicine Inc. have entered a multi-year collaboration for the discovery and development of precision medicines in oncology.

NGM Biopharmaceuticals Inc. inked a multiyear, multiproduct deal with Merck & Co. Inc. that is valued at a potential $450 million.

Orca Pharmaceuticals Ltd. and Astrazeneca plc will seek to leverage retinoic acid-related orphan nuclear receptor gamma inhibitors to address a wide range of autoimmune diseases.

Valeant Pharmaceuticals International Inc. is acquiring Salix Pharmaceuticals Ltd. in an all-cash deal valued at about $10.1 billion.

. . . AND MORE

Celgene International Sarl said the European Commission approved Revlimid for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Celltrion Healthcare Inc. launched Remsima (infliximab) in 12 European markets.

Intas Pharmaceuticals Ltd. launched its first biosimilar, filgrastim, in Europe, through its wholly owned subsidiary Accord Healthcare.